FDA Expands Indication for Boehringer Ingelheim’s Spevigo in Generalized Pustular Psoriasis

Indication of Spevigo (spesolimab-sbzo) expanded for the treatment of generalized pustular psoriasis in patients 12 years of age and older weighing ≥40 kg.

Source link
#FDA #Expands #Indication #Boehringer #Ingelheims #Spevigo #Generalized #Pustular #Psoriasis